Clinical trials for predictive medicine

Statistics in Medicine

Volumn 31, Issue 25, 2012, Pages 3031-3040

  Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trials; Predictive biomarkers; Predictive medicine; Re sampling methods

Indexed keywords

BIOLOGICAL MARKER; DIETHYLSTILBESTROL; PLACEBO; TRASTUZUMAB;

AGE; ALGORITHM; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER SIZE; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FUNCTIONAL STATUS; HUMAN; INTERNAL VALIDITY; MEDICINE; METASTASIS; OVERALL SURVIVAL; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RELIABILITY; SURVIVAL RATE; TREATMENT PLANNING; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84867439073     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5401     Document Type: Article

References (19)

1. Simon R. An agenda for clinical trials: Clinical trials in the genomic era. Clinical Trials 2004; 1:468-470.
2. Simon R. New challenges for 21st century clinical trials. Clinical Trials 2007; 4:167-169.
3. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. British Journal of Cancer 1976; 34:585-612.
4. Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II Analysis and examples. British Journal of Cancer 1977; 35:1-39.
5. ISIS-2 Collaborative Group. Randomised trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 2:349-360.
6. Dixon DO, Simon R. Bayesian subset analysis. Biometrics 1991; 47:871-881.
7. Sawyers CL. The cancer biomarker problem. Nature 2008; 452:548-552.
8. Simon R. A roadmap for developing and validating therapeutically relevant genomic classifiers. Journal of Clinical Oncology 2005; 23:7332-7341.
9. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research 2005; 10:6759-6763.
10. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials: Supplement and Correction. Clinical Cancer Research 2006; 12:3229.
11. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Statistics in Medicine 2005; 24:329-339.
12. Simon R. Using genomics in clinical trial design. Clinical Cancer Research 2008; 14:5984-5993.
13. Simon R. Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Review of Molecular Diagnostics 2008; 2(6):721-729.
14. Simon R, Wang SJ. Use of genomic signatures in therapeutics development. The Pharmacogenomcs Journal 2006; 6:1667-1673.
15. Wang SJ, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 2007; 6:227-244.
16. Jiang W, Freidlin B, Simon R. Biomarker adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defined subset effect. Journal of the National Cancer Institute 2007; 99:1036-1043.
17. Freidlin B, Simon R. Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clinical Cancer Research 2005; 11:7872-7878.
18. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design for predictive analysis of clinical trials. Clinical Cancer Research 2010; 16(2):691-698.
19. Byar D. Treatment of prostatic cancer: Studies by the Veterans Administration Cooperative Urological Research Group. New York Academy of Medicine 1972; 48(5):751-766.